Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $25.9 million.

  • Ocular Therapeutix's Non-Current Assets rose 5298.56% to $25.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $86.0 million, marking a year-over-year increase of 1957.18%. This contributed to the annual value of $25.9 million for FY2025, which is 5298.56% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Non-Current Assets of $25.9 million as of Q4 2025, which was up 5298.56% from $23.9 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Non-Current Assets high stood at $25.9 million for Q4 2025, and its period low was $12.7 million during Q2 2022.
  • In the last 5 years, Ocular Therapeutix's Non-Current Assets had a median value of $18.1 million in 2025 and averaged $17.8 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Non-Current Assets skyrocketed by 7135.46% in 2023, and later plummeted by 1783.58% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Non-Current Assets (Quarter) stood at $13.6 million in 2021, then soared by 44.71% to $19.7 million in 2022, then increased by 0.83% to $19.8 million in 2023, then dropped by 14.51% to $16.9 million in 2024, then surged by 52.99% to $25.9 million in 2025.
  • Its last three reported values are $25.9 million in Q4 2025, $23.9 million for Q3 2025, and $18.0 million during Q2 2025.